Gilead Just Walked Away From a $1 Billion Bet on Cancer

Arcus isn't alone in its TIGIT disappointment, by the way. The entire TIGIT class has stumbled. Multiple companies have hit similar walls, making the mechanism one of immuno-oncology's most expensive dead ends in recent memory.

What Gilead Keeps (and What It's Letting Go)

It's worth noting that Gilead didn't torch the entire relationship. The company still holds time-limited options on a few Arcus assets: AB801 (an AXL inhibitor in clinical trials), AB598 (an anti-CD39 antibody, also clinical-stage), an MRGPRX2 antagonist in preclinical work, and an unnamed TNF small-molecule inhibitor.

But the scope of the partnership has narrowed dramatically. The original 2020 deal was structured like an all-you-can-eat buffet: Gilead paid $175 million in cash and $200 million in equity upfront, with opt-in fees ranging from $150 million to $275 million per program. In November 2021, Gilead exercised options on three programs for $725 million. A 2024 amendment added another $320 million equity investment, pushing Gilead's ownership stake to 33%.

All told, Gilead invested well over a billion dollars across the life of the collaboration. Letting the early-stage options expire without payment is a clear signal: the company is reallocating capital elsewhere.

Gilead's Oncology Playbook Has Changed

If you're wondering whether Gilead is retreating from cancer entirely, the answer is a definitive no. The company has been on an acquisition spree that makes the Arcus pullback look like strategic pruning rather than retreat.

In February 2026, Gilead announced its agreement to acquire Arcellx for $7.8 billion, snagging a next-generation cell therapy for multiple myeloma that's under FDA review; the deal closed in late April 2026. It also agreed to buy Tubulis for roughly $3 billion in April 2026, adding a cutting-edge antibody-drug conjugate (ADC) platform to its toolkit. Think of ADCs as guided missiles: antibodies that deliver toxic payloads directly to cancer cells while (mostly) sparing healthy tissue.

Gilead also has Trodelvy (sacituzumab govitecan), an ADC it acquired in the $21 billion Immunomedics deal back in 2020. Phase 3 data showed significant improvements in progression-free survival for first-line metastatic triple-negative breast cancer, a notoriously difficult disease with few good treatment options.

The pattern is clear. Gilead is pivoting from partnered checkpoint inhibitor combos toward fully owned assets in ADCs and cell therapy, two of the hottest areas in oncology right now.

What Happens to Arcus?

Arcus isn't exactly left empty-handed, but the road ahead just got lonelier. The company's stock took a hit on the trial halt news, even though shares had gained 208% over the prior year.

The company's new crown jewel is casdatifan, an oral HIF-2α inhibitor for kidney cancer. It's running a Phase 3 trial (PEAK-1) against cabozantinib in patients who've already tried immunotherapy. An AstraZeneca collaboration pairs casdatifan with a PD-1/CTLA-4 bispecific antibody in first-line metastatic kidney cancer.

Arcus also has quemliclustat, a CD73 inhibitor now advancing independently in a Phase 3 study for first-line pancreatic cancer. These programs were previously co-developed with Gilead; now Arcus flies solo.

The company's finances tell a tougher story. Arcus is burning cash at a meaningful clip, and running multiple Phase 3 trials independently is expensive. Very expensive.

The Bigger Picture

The immuno-oncology landscape is evolving fast, and this split reflects a broader shift in how big pharma thinks about partnerships. The action has moved from single-agent checkpoint inhibitors to combination therapies: ADCs paired with immunotherapy, bispecific antibodies, and personalized cell therapies.

Merck's Keytruda remains the undisputed king, winning trial after trial and embedding itself deeper into treatment guidelines. Competing against it with a TIGIT combo was always a high-risk bet. Gilead placed that bet, watched it fail, and is now redirecting resources toward areas where it can own the entire value chain.

For Wall Street, the reaction has been muted on Gilead's side. Analysts maintain a Moderate Buy consensus with an average price target of $157.35, representing over 20% upside from recent trading near $130. Morgan Stanley has the stock at $175. The market seems to view the Arcus pullback not as a loss of confidence in Gilead's oncology ambitions, but as a rational capital allocation decision.

Sometimes the smartest move in a poker game isn't doubling down. It's folding a bad hand while you still have chips to play.

Why Esperion Just Ghosted Wall Street

Esperion Therapeutics is leaving Nasdaq after a decade-long stock collapse, even as its cholesterol drugs post triple-digit revenue growth. Healthcare PE firm ARCHIMED is paying a 58% premium in a deal worth up to $1.1 billion, and the reasons why say a lot about what's broken in small-cap biotech.